{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T20:06:42Z","timestamp":1775074002214,"version":"3.50.1"},"reference-count":50,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anti-infective Therapy"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1080\/14787210.2024.2400703","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T10:24:50Z","timestamp":1725531890000},"page":"925-934","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2913-2042","authenticated-orcid":false,"given":"Jordan R.","family":"Covvey","sequence":"first","affiliation":[{"name":"Division of Pharmaceutical, Administrative and Social Sciences, Duquesne University School of Pharmacy, Pittsburgh, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9019-8847","authenticated-orcid":false,"given":"Anthony J.","family":"Guarascio","sequence":"additional","affiliation":[{"name":"Division of Pharmacy Practice, Duquesne University School of Pharmacy, Pittsburgh, PA, USA"},{"name":"Department of Pharmacy, Allegheny General Hospital, Pittsburgh, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,9,8]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2016.02.009"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad109"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad556"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2016.02.004"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra070741"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-019-0706-5"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2017.00055"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04987-14"},{"key":"e_1_3_4_13_1","unstructured":"US Food and Drug Administration. FDA approves new treatment for pneumonia caused by certain difficult-to-treat bacteria. 2023 May 23 [cited 2024 May 24]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-pneumonia-caused-certain-difficult-treat-bacteria"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad093"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2008.04.002"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00184-6"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2020.08.021"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.10.033"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu613"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30796-9"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.107047"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11060723"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2023.08.029"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02142-21"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01258-23"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2210"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280231204566"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.709974"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2017.104"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2022.05.011"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad095"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00781-22"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa208"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02534-19"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00312-23"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad096"},{"issue":"2","key":"e_1_3_4_37_1","first-page":"S934","article-title":"LB2306. Population pharmacokinetic (PPK), pharmacokinetic\/pharmacodynamic attainment (PTA), and clinical pharmacokinetic\/pharmacodynamic (PK\/PD) analyses for sulbactam-durlobactam (SUL-DUR) to support dose selection for the treatment of Acinetobacter baumannii-calcoaceticus complex (ABC) infections","volume":"9","author":"Bhavnani SM","year":"2022","unstructured":"Bhavnani SM, Rubino CM, Hammel JP, et al. LB2306. Population pharmacokinetic (PPK), pharmacokinetic\/pharmacodynamic attainment (PTA), and clinical pharmacokinetic\/pharmacodynamic (PK\/PD) analyses for sulbactam-durlobactam (SUL-DUR) to support dose selection for the treatment of Acinetobacter baumannii-calcoaceticus complex (ABC) infections. OFID. 2022;9(Suppl 2):S934.","journal-title":"OFID"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa119"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01089-18"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00794-19"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00071-20"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01506-19"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac092"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1381123"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae210"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00290-24"},{"key":"e_1_3_4_49_1","unstructured":"US Food and Drug Administration. Drugs@fda: FDA approved drugs - Unasyn. [cited 2024 May 30]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=050608"},{"key":"e_1_3_4_50_1","unstructured":"Zai Lab. Zai Lab and innoviva specialty therapeutics announce NMPA approval for XACDURO\u00ae (sulbactam-durlobactam or SUL-DUR) for hospital-acquired and ventilator-associated pneumonia caused by Acinetobacter baumannii-calcoaceticus complex in China. 2024 May 20 [cited 2024 May 24]. Available from: https:\/\/ir.zailaboratory.com\/news-releases\/news-release-details\/zai-lab-and-innoviva-specialty-therapeutics-announce-nmpa"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2004.00987.x"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00312-23"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01228-23"},{"key":"e_1_3_4_54_1","unstructured":"Lexi-Drugs. Hudson (OH): Lexicomp. Available from: http:\/\/online.lexi.com\/"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2024.2351026"}],"container-title":["Expert Review of Anti-infective Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14787210.2024.2400703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T05:56:41Z","timestamp":1732859801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14787210.2024.2400703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,8]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1080\/14787210.2024.2400703"],"URL":"https:\/\/doi.org\/10.1080\/14787210.2024.2400703","relation":{},"ISSN":["1478-7210","1744-8336"],"issn-type":[{"value":"1478-7210","type":"print"},{"value":"1744-8336","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-07-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}